NCT06885970 (Cytisin-angio) is a clinical trial of Cytisinicline administration in Smoking Cessation, sponsored by University of Athens.

Who is sponsoring NCT06885970?

NCT06885970 is sponsored by University of Athens.

What drugs are being tested in NCT06885970?

Interventions in NCT06885970: Cytisinicline administration.

What condition does NCT06885970 study?

NCT06885970 studies Smoking Cessation, Arterial Stiffness, Endothelial Dysfunction.

Is NCT06885970 still recruiting?

NCT06885970 is currently recruiting now. Last updated 2 April 2025.

Last reviewed 2025-04-02 · How we verify

NCT06885970: Cytisin-angio

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of Cytisine Treatment for Smoking Cessation on Cardiovascular Function in Adult Smokers

Recruiting now Last updated 2 April 2025

What this trial tests

trial testing Cytisinicline administration in Smoking Cessation in 200 participants. Currently enrolling.

Timeline

12 November 2024

Primary endpoint
22 July 2025

10 August 2025

Quick facts

Lead sponsor	University of Athens
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	200
Start date	12 November 2024
Primary completion	22 July 2025
Estimated completion	10 August 2025
Sites	1 location across Greece

Drugs / interventions tested

Cytisinicline administration — full drug profile →

Conditions studied

Smoking Cessation — all drugs for Smoking Cessation →
Arterial Stiffness — all drugs for Arterial Stiffness →
Endothelial Dysfunction — all drugs for Endothelial Dysfunction →

Sponsor

University of Athens

Who can join

Adults 18 to 75, any sex, with Smoking Cessation or Arterial Stiffness. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Introduction: Pharmacological interventions can enhance smoking cessation success and long-term abstinence. Cytisine, a plant derived alkaloid, is a selective partial agonist at alpha-4 beta-2 nicotinic acetylcholine receptors, which are crucial in nicotine dependence. Aim of the Study The primary objective of this observational study is to evaluate the efficacy of cytisine in a standard 25-day dosing regimen among adult smokers and users of alternative nicotine products (e-cigarettes or heated tobacco). The study will assess the impact of cytisine on cardiovascular function, including arterial stiffness, cardiac deformation, and endothelial glycocalyx integrity. The secondary aim is to determine relapse rates post-treatment, treatment side effects, and new cardiovascular events during the treatment period and at six-month follow-up. Materials and Methods: This observational study will recruit smokers visiting the smoking cessation unit at the 2nd Department of Cardiology, Attikon University Hospital, Athens. All participants will receive counseling and treatment from the attending physician. A minimum of 200 participants will be enrolled, categorized into: • At least 50 receiving cytisine in the standard dosing regimen: Days 1-3: 1 tablet every 2 hours (6 tablets daily) Days 4-12: 1 tablet every 2.5 hours (5 tablets daily) Days 13-16: 1 tablet every 3 hours (4 tablets daily) Days 17-20: 1 tablet every 5 hours (3 tablets daily) Days 21-25: 1-2 tablets daily * At least 50 receiving nicotine replacement therapy * At least 50 receiving prolonged cytisine therapy (3 mg, three times daily for 12 weeks) * At least 50 who do not intend to quit smoking (control group) Assessments will be conducted at baseline, one month, and six months post-recruitment. The following measurements will be performed: A. Arterial Stiffness: Pulse wave velocity (cf-PWV) using the Complior device to measure arterial stiffness, Augmentation index and pulse wave velocity using the Arteriograph device via brachial artery cuff. B. Endothelial Glycocalyx Integrity: Perfused boundary region (PBR) assessment of sublingual microvasculature using a Sidestream Dark Field (SDF) camera. C. Cardiac Function: Left ventricular ejection fraction (LVEF), myocardial strain (GLS), and myocardial work assessment via speckle-tracking echocardiography (Echopac 203, GE Horten Norway).The investigators will also calculate myocardial work (MW) using pressure-strain loop analysis. D. Oxidative Stress: Plasma malondialdehyde (MDA) and protein carbonyl (PC) levels measured via spectrophotometry. E. Smoking Cessation Monitoring: Exhaled carbon monoxide (CO) measured using a commercial device (Smokelyzer, Bedfont Scientific Ltd.). This study aims to provide valuable insights into cytisine's effectiveness in smoking cessation and its impact on cardiovascular health.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The effects of cytisinicline for smoking cessation on arterial stiffness, endothelial function, and myocardial performance: a pilot study.
Ikonomidis I, Thymis J, Kostelli G, Katogiannis K, et al · · 2025 · cited 1× · PMID 40469528 · DOI 10.1093/ehjimp/qyaf062

Verify or expand the search:

Other recruiting trials for Smoking Cessation

Currently open trials in the same condition.

NCT07420621 — Preliminary Effectiveness of Enhanced Text Message + Incentives · NA · recruiting
NCT07224087 — Development of a MHBC Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients · Phase 1 · recruiting
NCT07331519 — Integrating Smoking Cessation With Low-dose CT-screening for Lung Cancer · NA · recruiting
NCT07210567 — Mindfulness-based Ecological Momentary Intervention for Smoking Cessation Among Cancer Survivors · NA · recruiting
NCT07129590 — Trauma-Informed Care for Smoking Cessation for Pregnancy · NA · recruiting

Other University of Athens trials

Trials by the same sponsor.

NCT07469943 — The Effect of Sodium Glucose Co-trnasportert Type 2 Inhibitors on Arterial Stiffness, Endothelial Glycocalyx Thickness a · recruiting
NCT07254819 — Cotinus Coggygria Mouthwash and Halitosis and Oral Hygiene in Orthodontic Patients · NA · completed
NCT07069010 — Burnout Syndrome in the Intensive Care Unit Before and During a Palliative Care Trial · recruiting
NCT06766097 — Chios Mastic Toothpaste and Halitosis and Oral Hygiene in Orthodontic Patients · NA · not yet recruiting
NCT07324902 — The Effect of Lipoprotein (a) on Arterial Stiffness, Endothelial Function and Myocardial Deformation · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06885970 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Athens
Last refreshed: 2 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06885970.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing